×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SOMMY – sumitomo chem unsp/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SOMMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/8
03:16 pm
sommy
Sumitomo Biorational Company Marks Official Launch with Inauguration Event [Yahoo! Finance]
Neutral
Report
Sumitomo Biorational Company Marks Official Launch with Inauguration Event [Yahoo! Finance]
3/23
08:23 am
sommy
Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa [Yahoo! Finance]
Medium
Report
Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa [Yahoo! Finance]
2/20
06:27 pm
sommy
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript [Seeking Alpha]
Low
Report
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript [Seeking Alpha]
2/20
04:07 am
sommy
Sumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatment [MSNBC.com]
High
Report
Sumitomo Pharma shares plunge nearly 16% despite greenlight for Parkinson's treatment [MSNBC.com]
2/19
10:07 pm
sommy
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment [MSNBC.com]
High
Report
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment [MSNBC.com]
2/19
09:17 pm
sommy
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment [CNBC]
High
Report
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment [CNBC]
2/7
10:17 pm
sommy
Assessing Sumitomo Chemical (TSE:4005) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Sumitomo Chemical (TSE:4005) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]
2/4
08:43 pm
sommy
Sumitomo Chemical Co Ltd (SOMMF) Q3 2026 Earnings Call Highlights: Strong Core Operating Income ... [Yahoo! Finance]
Low
Report
Sumitomo Chemical Co Ltd (SOMMF) Q3 2026 Earnings Call Highlights: Strong Core Operating Income ... [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Boston Biomedical, Inc. Announces Investment by its Parent Company in MPM Oncology Innovations Fund
3.8%
10/11 Nihon Medi-Physics Launches In-house Production of Molybdenum-99 3.0%
11/22 Form F-6EF Sumitomo Chemical Co., Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary 2.3%
5/14 Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors 2.3%
4/6 Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis 1.9%
12/12 Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia 1.5%
5/10 Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia 1.1%
8/8 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.0%
7/30 Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder 0.8%
6/6 Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis 0.7%
10/11 Nihon Medi-Physics Launches In-house Production of Molybdenum-99 3.0%
11/22 Form F-6EF Sumitomo Chemical Co., Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary 2.3%
5/14 Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors 2.3%
4/6 Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis 1.9%
12/12 Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia 1.5%
5/10 Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia 1.1%
8/8 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 1.0%
7/30 Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder 0.8%
6/6 Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis 0.7%
TOP News Decliners
3/26
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia
-7.3%
9/27 Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -4.3%
3/6 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.7%
4/12 Inspired By Nature, Zymergen Brews High-Performance Bio-Electronics [Forbes] -2.2%
5/30 Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors -1.8%
7/31 Nufarm Announces Placement Of $97.5 Mln Preference Securities To Sumitomo Chemical Co [Reuters] -1.5%
8/14 Sunovion Receives 2018 Corporate Responsibility and Leadership Awards from United Way of Tri-County and Expands Partnership For 8th Annual Community Service Program -1.5%
2/11 For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials [Forbes] -1.3%
9/28 Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019 -1.3%
6/12 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma -1.0%
9/27 Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -4.3%
3/6 SUMITOMO CHEM C/ADR (OTCMKTS: SOMMY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.7%
4/12 Inspired By Nature, Zymergen Brews High-Performance Bio-Electronics [Forbes] -2.2%
5/30 Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors -1.8%
7/31 Nufarm Announces Placement Of $97.5 Mln Preference Securities To Sumitomo Chemical Co [Reuters] -1.5%
8/14 Sunovion Receives 2018 Corporate Responsibility and Leadership Awards from United Way of Tri-County and Expands Partnership For 8th Annual Community Service Program -1.5%
2/11 For The First Time Ever, A Drug Developed By AI Will Be Tested In Human Trials [Forbes] -1.3%
9/28 Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019 -1.3%
6/12 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma -1.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: